Articles

The 9th Euretina Congress took place during May in Nice, France and was attended, according to the organisers, by around 1700 delegates. This was a seminal event and will be the last of its kind as next year it will join forces with ESCRS (European Society of Cataract and Refractive Surgeons) in Paris from 2–8 September.

The cataract surgery technology landscape including pipeline products at varying development stages comes under scrutiny in a new report released this month.

Results of the evaluation of two-year post-surgical safety and efficacy of canaloplasty to treat open angle glaucoma (OAG) have been published in the Journal of Cataract and Refractive Surgery. Dr Richard A Lewis et al., concluded that the procedure was safe and effective in reducing IOP in adult OAG patients.

Novagali Pharma, the French pharmaceutical ophthalmic company, is to conduct a Phase III clinical trial of Catioprost (Nova21027) its Investigational New Drug Application (IND).

Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.

Non governmental organisations have come together to draw attention to the inequalities in eye care for women worldwide.

The world's largest eye bank, The Tampa Lions Eye Institute for Transplant and Research, Inc. in Florida, which has supplied over 30,000 corneas for transplant and 50,000 eyes for research worldwide over the past 30 years, is to open a state-of-the-art research facility.

A diabetic retinopathy (DR) progression biomarker software has been developed with the research institute AIBILI (Association for Biomedical Research and Innovation in Light and Image) and Critical Health.

Central retinal vein occlusion (CRVO) is caused by obstruction of the central retinal vein that that leads to a back up of blood and fluid in the retina, resulting in retinal injury and loss of vision.

Findings, reported online this week,in advance of print in the Proceedings of the National Academy of Sciences (PNAS), are suggesting that the protein kinase JNK1 may have a key role in the development of retinopathy in premature babies.

Three professors from the UCL Institute of Ophthalmology are to become fellows of the Association for Research in Vision and Ophthalmology (ARVO) in its first honours list.

A new collaboration between Oxford BioMedica and Sanofi-Aventis is to develop and commercialise gene therapy treatments for retinal degenerative diseases such as Stargardt disease, the form of early-onset macular degeneration and Usher syndrome, a relatively rare genetic disease where sufferers are born deaf and lose vision within the first 10 years of life.

Ophthotech Corp. has announced positive results of a phase I clinical study evaluating E10030, its novel anti-platelet derived growth factor (anti-PDGF) in conjunction with an anti-vascular endothelial growth factor (anti-VEGF), to treat wet age-related macular degeneration (wet AMD).

Merck & Co., Inc. and Santen Pharmaceutical Co., Ltd., have agreed a worldwide licensing agreement for tafluprost, a prostaglandin analogue under investigation in the US.

Patients suffering from AMD have experienced long-term benefits from using the Macular Health vitamin supplement following the second phase of the Multifocal Electroretinogram (MERG) study at the Callahan Eye Foundation Hospital at the University of Alabama Birmingham (US).

An OTEurope story we ran a couple of weeks ago clearly resonated with reader, Peter Raus in Belgium. Read on to see what he thought.

Visiogen is reporting significant progress in the development of the Synchrony IOL, including the completion of the US phase III study, the formation of Visiogen Europe GmbH and the commencement of commercialization in Europe.

From Facebook to Twitter, individuals are embracing the opportunity to participate in online publishing at an unprecendented rate. Communities of users interact globally, minute-to-minute within huge databases of content that they themselves create.

The training component of the Mercy Vision programme, onboard the world's largest non-governmental hospital ship, is to receive $50,000 from the Alcon Foundation.

When injecting silicone oils with a viscosity of 5000 mPas, which are used frequently, retinal surgeons often reach limits of applicability.

“As we move into the 21st century the role of the IOL will evolve allowing better outcomes in cataract surgery and find new roles in surgery to improve vision such as through the treatment of presbyopia.”

New guidelines, designed to improve the management and diagnosis of chronic open angle glaucoma (COAG) and ocular hypertension have received a cautious commendation from the ophthalmic community.

Ultralase has become the first and only national provider to have all its UK surgeons accredited by the Royal College of Ophthalmologists (RCOphth).

The pioneering stem cell therapy, developed by British researchers to tackle AMD, has received the financial backing of pharma giant, Pfizer Inc., which is expected to pump in £50 million over the next three to five years.

You're an ophthalmologist? You use social media? Will Twitter change the way doctors practice medicine?

Six doctors are the recipients of the Alcon Research Institute (ARI) awards for their outstanding research contributions in the field of ophthalmology and vision science.

The Visante omni is the first system to combine OCT and Placido disk technologies, providing comprehensive anterior and posterior topography for improved patient selection and care.

From Facebook to Twitter, individuals are embracing the opportunity to participate in online publishing at an unprecedented rate. Communities of users interact globally, minute-to-minute within huge databases of content that they themselves create.

A worldwide licensing agreement for tafluprost, preserved and preservative-free formulations, has been announced between Merck & Co Inc., and Santen Pharmaceutical Co Ltd.

Interim analysis of Phase II trials for fenretinide and its use in the treatment of geographic atrophy (GA) are looking positive, according to Sirion Therapeutics, Inc.